Tissue Thromboplastin Induced Reversible DIC and Heparin-Enhanced Inhibitors in Dogs

Summary

Reversible acute disseminated intravascular coagulation (DIC) has been induced in dogs by intravenous injection of homologous tissue thromboplastin. There was no measurable consumption of antithrombin III and heparin cofactor II even if fibrinogen was reduced during DIC by more than 80% of its baseline. The prothrombin level remained practically constant. These data correspond to the generation of a few nanomoles of thrombin in vivo with subsequent pseudo-first order inactivation by the major thrombin inhibitors. An ex vivo measure of the pseudo-first order rate constant (dynamic thrombin inhibitory capacity, DTIC) was a sensitive probe of circulating heparin. There was no change of DTIC during DIC in the absence of exogenous heparin suggesting that heparin-like endogenous glycosaminoglycans were not released in substantial amounts. Pretreatment with heparin efficiently inhibited the development of tissue thromboplastin induced DIC. This animal model may serve as a tool for the study of glycosaminoglycan anticoagulants in vivo.

Key words

Reversible DIC in dogs - Antithrombin III - Heparin cofactor II - Glycosaminoglycans

• References

• 1 Rosenberg RD. Heparin-Antithrombin-System. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds.) J B Lippincott Company; Philadelphia, Toronto: 1982
• 2 Barrowcliffe TW, Thomas DP. Antithrombin III and heparin. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds.) Churchill Livingstone; Edingburgh: 1981
• 3 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombos Diathes Haemorrh 1965; 13: 516-530
• 4 Briginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma: I. Separation and partial purification. Arch Biochem Biophys 1974; 161: 683-690
• 5 Briginshaw GF, Shanberger JN. Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factorX. Thromb Res 1974; 4: 463-477
• 6 Tollefsen DM, Blank MK. Detection of a new heparin dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
• 7 Griffith MJ, Carraway T, White GC, Dombrose FA. Heparin cofactor activities in a family with hereditary antithrombin III deficiency: Evidence for a second heparin cofactor in human plasma. Blood 1983; 61: 111-118
• 8 Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255: 10081-10090
• 9 Jordan R, Beeler D, Rosenberg R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-2913
• 10 Griffith MJ. Measurement of the heparin enhanced antithrombin III/ thrombin reaction rate in the presence of synthetic substrates. Thromb Res 1982; 25: 245-253
• 11 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
• 12 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 13 Griffith MJ, Marbet GA. Dermatan sulfate and heparin can be fractionated by affinity for heparin cofactor II. Biochem Biophys Res Commun 1983; 112: 663-670
• 14 Downing MR, Bloom JW, Mann KG. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry 1978; 17: 2649-2653
• 15 Penick GD, Roberts HR, Webster WP, Brinkhous KM. Hemorrhagic states secondary to intravascular clotting. Arch Path 1958; 66: 709-714
• 16 Gurewich V, Nunn T, Lipinski B. Activation of intrinsic or extrinsic blood coagulation in experimental venous thrombosis and disseminated intravascular coagulation: pathogenetic differences. Thromb Res 1979; 14: 931-940
• 17 Collen D, Matsuo O, Stassen JM, Kettner C, Shaw S. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982; 99: 76-83
• 18 Owen CA, Mann KG, McDuffie FC. The turnover in normal dogs of prothrombin and its fragments, effect of induced intravascular coagulation. Thromb Haemostas 1979; 42: 548-555
• 19 Bick RL, Bick MD, Fekete LF. Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Pathol 1980; 73: 577-583
• 20 Lammle B, Tran TH, Ritz R, Duckert F. Plasma prekallikrein, factor XII, antithrombin III, Q-inhibitor and a2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol 1984; 82: 396-404
• 21 Cooper HA, Bowie EJW, Owen CA. Chronic induced intravascular coagulation in dogs. Am J. Physiol 1973; 225: 1355-1358
• 22 Smith HP, Warner ED, Brinkhous KM. Prothrombin deficiency and the bleeding tendency in liver injury (chloroform intoxication). J Exp Med 1937; 66: 801-811
• 23 Griffith MJ. Kinetics of the heparin-enhanced antithrombin III/ thrombin reaction. J Biol Chem 1982; 257: 7360-7365
• 24 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta haematol (Basel) 1957; 17: 237-246
• 25 Blomback B, Blomback M. Purification of human and bovine fibrinogen. Ark Kemi 1956; 10: 415-443
• 26 Teger-Nielsson AC, Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 203-409
• 27 Morita T, Iwanaga S, Suzuki T. The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venom and characterization of the new active intermediates. J Biochem 1976; 79: 1089-1108
• 28 Briet E, Noyes CM, Roberts HR, Griffith MJ. Cleavage and activation of human prothrombin by Echis carinatus venom. Throm-bos Res 1982; 27: 591-600
• 29 Kirchhof BRJ, Vermeer C, Hemker HC. The determination of prothrombin using synthetic chromogenic substrates, choice of a suitable activator. Thromb Res 1978; 13: 219-232
• 30 Snedecor GW, Cochran WG. Statistical Methods, 6th edition. Ames, Iowa, USA 1978
• 31 Martinelli RA, Scheraga HA. Steady state kinetic study of the bovine thrombin-fibrinogen interaction. Biochemistry 1980; 19: 2343-2350
• 32 Bando M, Matsushima A, Hirano J, Inada Y. Thrombin-catalyzed conversion of fibrinogen to fibrin. J Biochem 1972; 71: 897-899
• 33 Ohlsson K. Comparison of affinity of trypsin for two a-macroglobulin fractions and for arantitrypsin in dog serum. Clin Chim Acta 1971; 32: 215-220
• 34 Gitel SN, Wessler S. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: Clinical implications. J Lab Clin Med 1979; 94: 481-488
• 35 Colman RW, Marder VJ. Disseminated intravascular coagulation (DIC): Pathogenesis, pathophysiology, and laboratory anomalies. In: Hemostasis and Thrombosis Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds.) J B Lippincott Company; Philadelphia, Toronto: 1982
• 36 Marder VJ, Martin SE, Colman RW. Clinical aspects of consumptive thrombohemorrhagic disorders. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds. J B Lippincott Company; Philadelphia, Toronto: 1982
• 37 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Nat Acad Sci USA 1977; 74: 5260-5264
• 38 Jesty J, Silverberg SA. Kinetics of the tissue factor-dependent activation of coagulation factors IX and X in a bovine plasma system. J Biol Chem 1979; 254: 12337-12345
• 39 Jesty J, Morrison SA. The activation of factor IX by tissue factor -factor VII in a bovine plasma system lacking factor X. Thromb Res 1983; 32: 171-181
• 40 Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 60: 1353-1358
• 41 Penick GD, Roberts HR, Webster WP, Brinkhous KM. The prevention of hemorrhage with anticoagulants - An exploratory study of a paradox. Ann N Y Acad Sci 1964; 115: 67-77
• 42 Owen CA, Bowie EJ W. Effect of heparin on chronically induced intravascular coagulation in dogs. Am J Physiol 1975; 229: 445-454
• 43 Hoie J, Schenk WG. Impact of disseminated intravascular coagulation on central hemodynamics, and cardiac performance: An experimental study in dogs. Surgery 1971; 70: 685-92
• 44 Bergentz SE, Ljungqvist U, Levis DH. The distribution of platelets, fibrin and erythrocytes in various organs following thrombin infusion: An experimental study in dogs with and without antifibrinolytic therapy. Surgery 1972; 71: 190-195
• 45 Hoie J, Schenk WG. Experimental intravascular coagulation: Impairment of renal blood flow following thrombin infusion in the dog. J Trauma 1972; 12: 302-308
• 46 Hoie J, Schenk WG. Pulmonary hemodynamics and function in acute experimental disseminated intravascular coagulation. J Trauma 1973; 13: 887-894
• 47 Olsson P, Swedenborg J, Lindquist O. Effects of slow defibrinogena-tion on the canine lung. J Trauma 1974; 14: 325-329
• 48 Josephson S, Swedenborg J, Dahlgren SE. Delayed lung lesion in dogs after thrombin-induced disseminated intravascular coagulation. Acta Chir Scand 1974; 140: 431-435
• 49 Jastrzebski J, Amot RN, Hilgard P, Sykes MK. Thrombin-induced disseminated intravascular coagulation in the dog: I. Demonstration of microthrombin in the lung. Br J Anaesth 1975; 47: 654-657
• 50 Jastrzebski J, Hilgard P, Chakrabarti MK, Henry K, Sykes MK. Thrombin-induced disseminated intravascular coagulation in the dog. II. Cardiorespiratory changes during spontaneous and controlled ventilation. Br J Anesth 1975; 47: 658-666
• 51 Garner R, Evensen SA. Endotoxin-induced intravascular coagulation and shock in dogs: The role of factor VII. Br J Haematol 1974; 27: 655-668
• 52 Garner R, Chater BV, Brown DL. The role of complement in endotoxin shock and disseminated intravascular coagulation: Experimental observations in the dog. Br J Haematol 1974; 28: 393-401
• 53 Miiller-Berghaus G, Niepoth M, Rabens-Alles B, Rump E, Murano G. Antithrombin III concentration and antithrombin III substitution in experimental disseminated intravascular coagulation. Thromb Haemostas 1983; 50: 323
• 54 Hogg DH, Blomback B. The specificity of the fibrinogen-thrombin reaction. Thromb Res 1974; 5: 685-693
• 55 Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976; 58: 1136-1144
• 56 Walker FJ, Esmon CT. Interactions between heparin and factor Xa. Inhibition of prothrombin activation. Biochim Biophys Acta 1979; 405-415
• 57 Ofosu FA, Cerskus AL, Hirsh J, Smith LM, Modi GJ, Blajchman MA. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids and tissue factor. Br J Haematol 1984; 57: 229-238
• 58 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest 1983; 71: 1383-1391
• 59 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578
• 60 Nanninga LB. Molar concentrations of fibrinolytic components, especially free fibrinolysin, in vivo. Thrombos Diathes Haemorrh 1975; 33: 244-255
• 61 Bickford AF, Faylor FB, Sheena R. Inhibition of the fibrinogen-plasmin reaction by p-aminocarboxylic acids and alkylamines. Biochim Biophys Acta 1964; 92: 328-333
• 62 Griffith MJ. The heparin-enhanced antithrombin Ill/thrombin reaction is saturable with respect to both thrombin and antithrombin III. J Biol. Chem 1982; 267: 13899-13902